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                            During the first decades of the last century, because of improve-
ments in prevention and therapy of infectious diseases, better 
hygiene and socioeconomic conditions, and consequently 
increased life span, cardiovascular and cerebrovascular diseases 
rose to become the leading causes of death. In addition to age, 
there are other common risk factors for both cardiovascular 
disease and cancer (  1  ). Now that efforts to prevent cardiovascular 
diseases have been effective, cancer is rising as the major cause of 
death. A patient with a neoplasm or preneoplastic condition who 
undergoes cancer therapy or chemoprevention is now at a sub-
stantial risk for the deterioration of his or her cardiovascular 
health. In the past, this risk was less evident because the life span 
of a patient with metastatic disease was often too short to make 
the cardiovascular complications a major matter of concern. 
However, now that progress has been made in terms of early 
diagnosis, therapy, and survival, targeted drugs and combinations 
of two or three different agents have emerged, and intervention 
is more and more often used at the adjuvant stage; cardiotoxicity 
of cancer therapy is a pivotal issue. The medical community is 
becoming increasingly aware of its impact, as highlighted in sev-
eral recent reviews (  2    –    5  ). 
  Here, we summarize major aspects of cardiotoxicity of antican-
cer therapies and strongly recommend the creation of teams of 
cardiologists working with oncologists to build an interdisciplinary 
ﬁ  eld that could be termed cardio-oncology (  6  ). We also suggest 
that cardio-oncology teams develop guidelines to protect the 
oncology patient from the rising risk of cardiovascular side effects 
among anticancer therapies. 
          What Exactly Does Cardiotoxicity Mean? 
  The National Cancer Institute defines cardiotoxicity in very gen-
eral terms as “toxicity that affects the heart” (www.cancer.gov/dic-
tionary/). However, although it is well known that several cancer 
chemotherapeutics adversely affect the heart and the vascular 
system, and that a growing number of clinical trials (registered at 
    www  .  clinicaltrials  .  gov    ) are now studying long-term side effects of 
anticancer therapy, including cardiovascular events, a clear under-
standing of what cardiotoxicity is and how anticancer therapy 
stresses the cardiovascular system is lacking. One of the most accu-
rate clinical definitions of cardiotoxicity has been formulated by the 
cardiac review and evaluation committee supervising trastuzumab 
clinical trials, which defined drug-associated cardiotoxicity as one 
or more of the following: 1) cardiomyopathy in terms of a reduction 
in left ventricular ejection fraction (LVEF), either global or more 
severe in the septum; 2) symptoms associated with heart failure 
(HF); 3) signs associated with HF, such as S3 gallop, tachycardia, or 
both; 4) reduction in LVEF from baseline that is in the range of 
less than or equal to 5% to less than 55% with accompanying signs 
or symptoms of HF, or a reduction in LVEF in the range of equal 
to or greater than 10% to less than 55%, without accompanying 
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signs or symptoms (  7  ). This definition does not include subclinical 
cardiovascular damage that may occur early in response to some 
chemotherapeutic agents; thus, to date, an ideal definition is 
lacking. 
  The use of chemotherapeutic agents, radiation therapy, and 
molecular targeted therapies are all approaches that can injure the 
cardiovascular system, both at a central level by deteriorating the 
heart function and in the periphery by enhancing hemodynamic 
ﬂ  ow alterations and thrombotic events often latently present in 
oncology patients. Unfortunately, a comprehensive analysis of 
published data on cardiotoxicity is difﬁ  cult to perform and would 
be inadequate because oncology trials measuring vascular effects 
vary widely in their methods and deﬁ   nition of cardiotoxicity. 
Published data regarding risk factors are contradictory, longitudi-
nal studies on well-deﬁ  ned cohorts are insufﬁ  cient, and knowledge 
of the relationship between abnormalities identiﬁ  ed by noninva-
sive cardiac testing and clinical status of survival are not sufﬁ  ciently 
clear (  8  ). Moreover, in many cases, the primary literature is lacking 
in regard to the rate of the cardiovascular adverse events of anti-
neoplastic drugs, particularly for newer targeted therapies. In ad-
dition, the reported rates of cardiotoxicity were obtained from the 
available published literature; thus, they apply only to the available 
follow-up periods for each agent (  5  ). 
  Cardiotoxicity can develop in a subacute, acute, or chronic 
manner. Acute or subacute cardiotoxicity is characterized by either 
the occurrence of abnormalities in ventricular repolarization and 
electrocardiographic QT-interval changes, by supraventricular and 
ventricular arrhythmias, or by acute coronary syndromes and peri-
carditis and/or myocarditis-like syndromes, observed any time from 
the initiation of therapy up to 2 weeks after termination of treat-
ment. Chronic cardiotoxicity may be differentiated in two subtypes 
based on the onset of clinical symptoms. The ﬁ  rst subtype occurs 
early, within 1 year after termination of chemotherapy, and the 
second occurs late, more than 1 year after chemotherapy. The most 
typical sign of chronic cardiotoxicity is asymptomatic systolic and/
or diastolic left ventricular dysfunction that leads to severe conges-
tive cardiomyopathy and that may ultimately lead to death (  8  ,  9  ).   
    How Cardiotoxicity Manifests Itself: Effects of Anticancer 
Therapy on the Cardiovascular System 
  Several publications (  2    –    4  ,  7    –    12  ) have focused on the cardiotoxic-
ity of specific classes of cancer therapeutic agents and recently, 
we have begun to see a global analysis of the diverse classes to-
gether (  5  ). We have provided a summary of the cardiovascular 
toxic effects produced by different drugs and therapeutic agents 
(  Table 1  ). Briefly, anthracyclines can generate congestive heart 
failure (CHF) and left ventricular dysfunction. The occurrence of 
CHF is dose- and schedule-dependent; left ventricular dysfunc-
tion is more frequently observed in women, in patients with a 
personal history of cardiac disease, and after mediastinal X-ray 
therapy (  12  ). The risk of cardiotoxic adverse events increases 
when anthracycline chemotherapy is administered concurrently 
or sequentially before adjuvant therapy with trastuzumab, a 
monoclonal antibody specific for the HER2 protein (  11  ). 
Mitoxantrone, which is a derivative of anthraquinone, induces 
acute myocarditis and arrhythmia during infusion. Antimetabolite 
agents, such as capecitabine or cytarabine, can induce ischemia, 16   Review | JNCI  Vol. 102, Issue 1  |  January 6, 2010
pericarditis, CHF, and cardiogenic shock. In particular, cardio-
toxicity that is induced by fluoropyrimidines such as 5-fluoroura-
cil could be manifested by myocardial ischemia, as indicated by 
the electrocardiographic alterations that are occasionally observed 
during 5-fluorouracil administration and it is rate- and dose-de-
pendent. Antimicrotubule molecules, such as paclitaxel or vinca 
alkaloids, can cause sinus bradycardia, atrioventricular block, 
ventricular tachycardia, hypotension, CHF, and ischemia 
[reviewed in (  12  )]. HF that occurs after high-dose cyclophospha-
mide, ifosfamide, or mitomycin treatment is manifested by 
neurohumoral activation without concomitant cardiomyocyte 
necrosis. Mild functional mitral regurgitation may also develop 
in cyclophosphamide-treated patients (  13  ).       
  Hypotension or hypertension, arrhythmias, CHF, angioe-
dema, and left ventricular dysfunction are observed in patients 
treated with biological agents such as monoclonal antibodies, 
interleukins, and interferon-     (  12  ). Myocardial ﬁ  brosis  (  14  ), 
valvular heart disease, more frequently involving left-sided 
valves (  15  ), and endothelial cell damage (  16  ) can also occur fol-
lowing radiation therapy (  Table 1  ). The antiangiogenic and 
multitarget tyrosine kinase inhibitors (TKIs) sorafenib and 
sunitinib are associated with hypertension and cardiotoxicity 
(  3  ,  10  ,  17    –    19  ). The anti  –  vascular endothelial growth factor anti-
body bevacizumab is also associated with hypertension and in-
stances of thromboembolism, pulmonary hemorrhage, and 
pulmonary edema or gastrointestinal tract bleeding (  10  ). Thus, 
the antiangiogenesis class of drugs can also harbor cardiovascu-
lar toxicity, as indicated by a reduction of LVEF that over the 
long term may result in CHF (  2    –    4  ). Another class of agents that 
appear to have effects on vascular system is the selective estro-
gen receptor modulators. It has been shown that tamoxifen in-
duces a variation of low-density lipoprotein and high-density 
lipoprotein blood levels in a different manner than that induced 
by aromatase inhibitors (  20  ). Tamoxifen induces a decrease in 
total cholesterol and low-density lipoprotein levels and       an 
increase in triglyceride concentration, but no change has been 
reported for high-density lipoprotein serum concentration. 
Some evidence exists that tamoxifen reduces the incidence of 
myocardial infarction (  21  ). However, this apparent favorable 
effect of tamoxifen on the lipid proﬁ  le does not consistently 
translate into a beneﬁ  cial effect on the development or progres-
sion of cardiovascular diseases. On the contrary, tamoxifen may 
have a detrimental effect, with a substantially increased risk of 
venous thromboembolism, pulmonary embolism, and stroke 
due to its function as a partial estrogen agonist, a characteristic 
that is associated per se with the increased incidence of throm-
boembolic events (  Table 1  ).  
    Why Cardiotoxicity Happens: Mechanisms of Therapy-
Induced Damage to Heart and Blood Vessels 
  As expected, the mechanisms of cardiotoxicity vary widely among 
diverse chemotherapeutics (  22  ) (  Table 1  ). However, when exam-
ining individual mechanisms, some common themes emerge that 
may provide interesting targets to block or to overcome. The 
cardiovascular system has numerous different targets that can be 
subject to damage. First, some drugs directly damage cardiomyo-
cytes or cause inflammation of the pericardium. Second, some 
drugs affect the coagulation system and can promote blood clot-
ting in the vessels that predisposes to thromboembolic events and 
consequent cardiovascular and cerebrovascular ischemia. The 
impact of antineoplastic therapies on the coagulation cascade can 
be basically ascribed to damage to the intima of the vessels. 
Damage to peripheral circulation can impair circulation and pre-
dispose to thrombosis. Antiangiogenic drugs also have an impact 
on the interconnections of endothelial cells and are associated 
with changes in vessel structure and possibly with bleeding and 
hemorrhage. Third, hypertension, often seen with the antiangio-
genic agents, has acute and long-term effects on cardiac hypertro-
phy and insufficiency. Fourth, atrial fibrillation (AF), which is 
common in elderly indivi  duals,       can be exacerbated by anticancer 
treatments. Each of these four drug targets is discussed in greater 
detail below. 
    Direct Effects on the Heart.             Many drugs directly damage the 
cardiomyocytes or cause inflammation of the pericardium. 
Anthracyclines produce cardiac toxicity accompanied by an increase 
in myofibrillar disarray that is mediated by the signaling function of 
neuregulin 1     (  23  ,  24  ). In addition, the classic cytotoxic chemother-
apeutic agents, including anthracyclines, induce mitochondrial 
apoptosis pathways and free radical production (  25  ). The cardio-
toxic potential of anthracycline is enhanced by the concurrent or 
sequential administration of antibodies that target tyrosine kinase 
receptors, in particular trastuzumab (  26  ,  27  ). Trastuzumab is car-
diotoxic on its own and strikingly potentiates the cardiotoxic effects 
of anthracyclines. The trastuzumab target, ErbB2, is expressed on 
cardiomyocytes, where it exerts a protective effect on cardiac func-
tion (  28  ). Both HER receptors and their ligands are expressed in 
the heart and their activation creates a hypertrophic response (  29  ). 
In addition, heregulin  –  HER signaling promotes cell survival and 
growth and protects against apoptosis (  29  ). The ability of the heart 
to withstand stress is due, at least in part, to a protein network 
leading to cell survival that is activated by HER ligands and involves 
the activator protein-1 and the nuclear factor     B. Activator pro-
tein-1 regulates the expression of a group of cardiac proteins that 
are important in the development of cardiac hypertrophy, and 
nuclear factor     B regulates the genes that are involved in the cel-
lular response to stress and inflammation (  29  ). However, not all 
monoclonal antibodies that target Erb proteins induce damage to 
the heart. In fact, lapatinib, an oral TKI that targets ErbB1 (epidermal 
growth factor receptor)       and ErbB2 (HER2), was reported to show 
very little cardiotoxicity, although the different criteria used to 
define cardiotoxicity could have led to an underestimation of the 
actual incidence of cardiovascular adverse events (  30  ). These data 
suggest that factors such as antibody-directed cellular cytotoxicity 
may contribute to adverse events when using therapeutic anti-
bodies against cell surface receptors that are also expressed on 
cardiomyocytes. 
  A possible mechanism by which the taxane paclitaxel would 
cause cardiotoxicity is massive histamine release. Indeed, in 
animal studies, stimulation of histamine receptors in cardiac 
tissue has resulted in conduction disturbances and arrhythmias. 
Alternatively, paclitaxel-induced cardiotoxicity could be attrib-
uted to the induction of cardiac muscle damage via effects on 
subcellular organelles (  31  ). jnci.oxfordjournals.org    JNCI | Review 17
  The mechanisms by which several other chemotherapy drugs 
produce cardiovascular toxicities have also been investigated. 
5-Fluorouracil, a widely used chemotherapeutic, has direct toxic 
effects on vascular endothelium that involve endothelial nitric 
oxide (NO) synthase and lead to coronary spasms and endotheli-
um-independent vasoconstriction via protein kinase C (  32  ). Several 
new generation TKIs, for example, sorafenib and sunitinib, have 
been also been associated with direct cardiotoxicity (  3  ,  10  ). 
Cardiomyocytes from subjects who are being treated with imatinib 
appear to have endoplasmic reticula that have been activated in 
response to cellular stress, collapsed mitochondrial membrane 
potential, reduced ATP content, and to be more prone to cell death 
(  33  ). However, whether the observed cardiomyocyte cell damage 
represents clinical cardiotoxicity is still controversial (  34  ), as is the 
role of the protooncogene abl (a target of imatinib and similar 
compounds) in the physiology of the cardiomyocyte (  33  ,  35  ).   
    Effects on the Coagulation System.             Chemotherapy-induced 
effects on the coagulation system can promote blood clotting in the 
vessels, which is a precursor to thrombosis and thromboembolic 
events and sets the stage for consequent cardiovascular and/or 
cerebrovascular ischemia. Cancer is known to produce a prothrom-
botic state  —  Armand Trousseau diagnosed thrombosis as being 
related to cancer in 1865. The risk of thrombosis from cancer ap-
pears to be highest in cancer patients with metastatic disease and in 
those with established risk factors (  5  ). Life-threatening hemorrhage 
and arterial thromboembolism have been observed in patients 
being treated with agents that are broad-spectrum angiogenesis 
inhibitors, such as thalidomide and lenalidomide (  36  ). It is not 
known how angiogenesis inhibitors and vascular disrupting agents 
alter normal hemostasis; it is likely that they disrupt the function or 
the integrity of the vascular endothelium (  36  ,  37  ). Damage to the 
vessel can involve injury to the intimal layer or disruption of endo-
thelial cell  –  cell communication. In either case, the loss of integrity 
of the vessel lining activates the coagulation cascade. 
  Venous thromboembolism has been associated with several 
categories of chemotherapeutic agents: alkylating agents, angio-
genesis inhibitors, histone deacetylase inhibitors, and TKIs (  38    –
    40  ). In particular, the alkylating agent cisplatin can trigger platelet 
aggregation, enhance thromboxane formation by platelets, and 
activate arachidonic acid pathways in platelets (  31  ). 
  The risk of hemorrhage and thromboembolisms increases with 
the use of drugs that modify the expression pattern of adhesion 
molecules, such as integrins and cadherins, on endothelial cells, 
producing alterations on the cell  –  cell and cell  –  matrix connections 
and interruption of the endothelium integrity. For example, doxy-
cycline targets the adherens junction in vascular endothelial cells 
by inducing total vascular endothelial      -cadherin expression while 
decreasing vascular endothelial-cadherin phosphorylation (  41  ). 
Furthermore, it has been demonstrated that lenalidomide inhibits 
the vascular endothelial growth factor –  induced association between 
cadherin 5, CD31, and     -catenin (  42  ,  43  ).   
    Hypertension.             Hypertension and cancer often coexist in the same 
patient, and treatment with antiangiogenic agents exacerbates hy-
pertension, with acute and long-term effects on cardiac hypertro-
phy and insufficiency. In fact, high blood pressure is the most 
frequent comorbid condition reported in cancer registries (  44  ,  45  ). 
Hypertension is a common adverse effect in patients who are 
treated with bevacizumab, sorafenib, and sunitinib (  5  ). The mech-
anism of antiangiogenic therapy  –  related hypertension is not fully 
understood but it is thought to be related to vascular endothelial 
growth factor inhibition, which, through decreased NO-synthase 
activity, leads to decreases in NO production in the walls of arte-
rioles and other resistance vessels. NO is a natural vasodilator; 
thus, blocking its production promotes vasoconstriction and 
increases peripheral vascular resistance and blood pressure (  46  ). 
Moreover, the decreased endothelial NO synthase activity may 
stimulate plasminogen activator inhibitor-1 expression, leading to 
an increased risk of hypertension (  47  ).   
    Atrial Fibrillation.             AF, a common finding in the elderly, can be 
exacerbated by anticancer treatments and may complicate the out-
come of patients with malignancies as side effects of surgical or 
medical therapies (  48  ). AF may be due to patient stress but also can 
be induced by various cytostatic agents, such as ifosfamide, gemcit-
abine, melphalan, cisplatin, docetaxel, 5-fluorouracil, or etoposide, 
or by high doses of corticosteroids (  49  ,  50  ). 
  Inﬂ   ammation plays an important role in carcinogenesis and 
could provide a possible explanation for a relationship between AF, 
inﬂ  ammation, and cancer. 18.3% of patients with history of cancer 
had AF compared with 5.6% of patients without a history of cancer 
(  51  ). A statistically signiﬁ  cant elevation of serum levels of C-reactive 
protein were found in patients with AF (  52  ) and in patients with a 
history of cancer (  51  ), implying systemic inﬂ  ammation. However, 
cancer was not found to be an independent predictor of atrial ar-
rhythmias in multivariable analysis. Taken together, these data 
suggest that malignancy does not lead to AF per se, but does so 
through systemic inﬂ  ammation.     
    The Sliding Doors Concept 
  Given the variety of effects and mechanisms described above, there 
is an increasing awareness of the concept: “Is it time for oncolo-
gists to get to know their cardiologists?” (  53  ). A patient who has a 
comorbidity of cardiovascular disease and cancer could possibly 
have a different outcome depending on whether he or she was first 
seen by an oncologist or a cardiologist. For example, if a patient 
with a family history of heart disease and gastrointestinal tract 
cancer were to have an occult cardiovascular condition and an 
undiagnosed colon cancer with tumor-associated thrombophilia 
aggravating the cardiovascular condition, he or she might encoun-
ter either of two scenarios (  Figure 1  ). If the patient were to visit a 
cardiologist first, the diagnosis of cardiovascular risk would be 
made and appropriate medications prescribed to improve heart 
function and reduce thrombosis. However, the patient is at risk of 
being diagnosed later with tumor progression and poorer progno-
sis. If the patient were to go to an oncologist first, a colonoscopy 
examination would likely be suggested based on family history and 
if colon cancer were detected, the patient would undergo surgery 
and chemotherapy for the tumor. However, he or she might not be 
given a full cardiovascular workup other than a blood pressure test. 
The patient’s cancer may respond well to the therapeutic regimen, 
but his or her cardiovascular system might not; cardiotoxicity from 
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control of hypertension from an antiangiogenic agent could spell 
incumbent disaster. This example provides the basis for the in-
creasing necessity for communication between the cardiologist and 
oncologist and the creation of “cardio-oncology” interdisciplinary 
clinical units. Recent studies suggest that this approach can be 
pursued successfully (  54  ,  55  ).           
    Cardio-Oncologist’s Individual Risk Assessment 
  One important item needs to be addressed clinically: only a sub-
group of patients who are treated with certain chemotherapy, tar-
geted therapy, or chemoprevention regimen will develop 
cardiovascular complications, the risk being individual. An accu-
rate family and anamnesis (personal history) will lead to the iden-
tification of the patients at risk. Susceptibility to the development 
of cardiotoxicity of any kind and severity with anticancer therapy 
is a multifactorial characteristic that is determined by the interac-
tion between genetic and environmental factors. The genetic 
component is polygenic and different genes cooperate in an epi-
static manner. The modifier effect of epigenetic factors also con-
tributes to the genetic susceptibility to cardiotoxicity. Genetic 
influences have already been examined in patients taking anthracy-
clines (  56    –    58  ). Moreover, familial risk of coronary artery disease or 
CHF has been associated with an additional risk of developing 
these conditions in the treated population (  59  ). Age, sex, and other 
personal characteristics or events related to personal history, in-
cluding previous or concurrent therapies, can be included. 
  Cardiotoxicity of cancer chemotherapeutics is a problem for 
patients of all ages, but it increases with age. Toxicity can also de-
velop months after the last chemotherapy dose, and late reactions can 
   
    Figure 1    .             The “sliding doors” concept, an example of diverse outcomes 
based on ﬁ  rst diagnosis. There is a risk for diverse outcomes depending 
on whether the patient with both cardiovascular disease and cancer 
ﬁ  rst presents to a cardiologist or to an oncologist. The oncologist takes 
a tumor-centric perspective in diagnosis, and in the past might have 
been missing the incumbent cardiopathy of the individual. The cardiol-
ogist treats the cardiopathy correctly, but may not pick up early signs 
of cancer, thus the patient risks further progression and oncologic com-
plications. Teamwork should improve patient life expectancy, treating 
cancer while protecting the heart, or treating the heart and providing a 
thorough oncologic check up. 5-FU    =    ﬂ  uorouracil; FOLFOX    =    folinic acid 
(leucovorin), 5-FU and oxaliplatin; GI    =    gastrointestinal; HF    =    heart 
failure.         
be seen years later when they present as new-onset cardiomyopathy, 
often in patients who were treated for childhood neoplasms (  60  ). 
  Also, men and women have differences in risk of cardiotoxicity 
(  61  ). Premenopausal women are less likely than men of same age 
to develop atherosclerosis. However, after menopause, the levels of 
protective hormones drop and therefore the rate of atherosclerosis 
in women rapidly increases (  62  ). Thus, the sex of the patient is 
important to take into account in cardio-oncology. 
  Early identiﬁ  cation of patients who are at risk for cardiotoxicity 
should be a primary goal for oncologists in the development of 
personalized antineoplastic therapeutic strategies or interventions. 
The improvement of diagnostic tools in both cardiology and on-
cology has led to an increased number of patients who have been 
treated for cancer and diagnosed with cardiovascular disease. It 
may sometimes be necessary for oncology patients to undergo 
cardiothoracic surgery to survive heart problems, when their risk 
from cardiovascular disease outweighs their risk from cancer. 
Therefore, risk vs beneﬁ  t or risk vs risk evaluations should be per-
formed by a cardio-oncology team. 
  Recently published clinical cancer studies that screened partici-
pants on entry for cardiovascular conditions have revealed a high 
prevalence of subjects at cardiovascular risk (  3  ,  63  ). Schmidinger et 
al. (  3  ,  63  ) reported an observational single-center study of patients 
scheduled for TKI treatment with sorafenib and sunitinib who were 
analyzed for risk of coronary artery disease, cardiovascular history 
and evidence of coronary artery disease, hypertension, rhythm 
disturbances, or HF. The study reported a history of cardiovascular 
disease in 9.3% of the enrolled patients, as well as myocardial 
infarction (5.8%), HF (7%), rhythm disturbances (3.5%), and 
uncontrolled hypertension (3.5%). Many enrolled patients were at 
high cardiovascular risk because of hypertension (48.8%), hyper-
cholesterolemia (26.7%), diabetes mellitus (22%), or hypertriglyc-
eridemia (12.8%). These observations indicate that preexisting 
cardiac disease is often underestimated, but also that it is manage-
able if the patients have careful cardiovascular monitoring and 
cardiac treatment at the ﬁ  rst signs of myocardial damage (  3  ,  63  ). 
  Use of on-entry screening appears to be particularly important 
during chemoprevention of cancer, as highlighted by studies on 
nonsteroidal anti-inﬂ   ammatory drugs (NSAIDs) speciﬁ  c  for 
cyclooxygenase 2.       Although the use of aspirin is associated with a 
reduction in cardiovascular       risk, at least in men, treatment with 
some COX-2 speciﬁ  c NSAIDs has led to increases in adverse car-
diovascular effects. In the chemoprevention trial using the NSAID 
sulindac, 28.5% of enrolled patients were at low cardiovascular risk, 
31.5% at moderate risk, and 40% at high risk (  63  ). In this cohort, 
cardiovascular events were higher in the treated group (nine of 191) 
than in the placebo group (three of 184). However, when patients 
with a high baseline cardiovascular risk were excluded, the risk of 
cardiovascular complications became similar in the treated and 
placebo groups (  63  ). This ﬁ  nding that patients at high cardiovascular 
risk were more adversely affected by these drugs is in line with a 
recent meta-analysis that suggests that baseline cardiovascular risk 
is associated with adverse cardiovascular events linked to NSAID 
use (  64  ). It suggests that on-entry screening can indeed identify 
individuals at elevated risk of cardiotoxicity, who might then be 
treated either with a different, less cardiotoxic, agent or with the 
same agent along with cardioprotective agents. jnci.oxfordjournals.org    JNCI | Review 19
   
    Figure 2    .       A possible cardio-oncology team ﬂ  owchart. In a cardio-oncol-
ogy team effort, the oncologist and cardiologist should work together, 
evaluating the patient’s cardiovascular risk level as an integral part of 
the choice of cancer therapy. In addition, the patient is monitored 
throughout therapy and follow-up so that eventual cardiovascular alter-
ations can be detected in a timely manner and treated either by inter-
vention on the cardiovascular side or by modulation of the cancer 
therapy. Future trial protocols could include a series of candidate 
marker measurements, both instrumental and serological, in the initial 
evaluation stage as well as during the course of therapy to identify 
those most informative of risk potential. HF    =    heart failure. *Substantial 
changes in cardiovascular risk assessment; for example, a reduction in 
left ventricular ejection fraction (LVEF) from baseline greater than 5% to 
less than 55% with accompanying signs or symptoms of HF or a reduc-
tion in LVEF greater than 10% to less than 55%, without accompanying 
signs or symptoms.         
  The clinical trials that showed that celecoxib could prevent co-
lorectal adenomas recorded many deaths from adverse cardiovascu-
lar events (hazard ratio [HR] of death    =    2.3 at 200 mg of celecoxib 
twice daily and HR of death    =    3.4 at 400 mg of celecoxib twice daily) 
(  65    –    68  ). In these trials, patients who experienced cardiovascular 
problems were likely to have already had undetected high-risk con-
ditions when they enrolled in the trial. A detailed cardiovascular 
examination at recruitment would have probably identiﬁ  ed these 
patients and permitted the discovery of high-risk groups in which 
risk outweighs beneﬁ  t, as well as low risk groups in which the can-
cer chemoprevention beneﬁ  t predominates. We initially suggested 
that cardioprevention approaches could have been used with this 
class of drugs (  37  ); here we extend the concept of assessing cardio-
vascular risk factor to screening in prevention trials. Another re-
cently reported example of the importance of cardiovascular 
screening for cancer patients came from a trial of neoadjuvant hor-
monal therapy in men with prostate cancer, in which increased risk 
of mortality was found only in patients with multiple cardiovascular 
risk factors or a history of cardiovascular disease (  69  ).   
    Prediagnostic Tools: Instrumental and Medicinal 
Chemistry 
  Taken together, these data suggest that a baseline cardiovascular 
examination along with careful cardiovascular management could 
not only prevent adverse events from antineoplastic drugs but 
could also be used to exclude their use in potentially high-risk in-
dividuals and thereby enable assessment of the effectiveness of 
these therapeutic or prevention agents in low- and moderate-risk 
individuals. In the past, oncologists were not nearly so aware of 
cardiovascular complications, which have become more evident 
with longer survival after cancer diagnosis, the use of targeted 
therapies, and combinations of chemotherapies and targeted ther-
apies, as well as experience in chemoprevention trials. It is impor-
tant to highlight that the choice of the therapeutic approach and 
the survival prognosis depend on the fine balance between cancer 
treatment and cardiovascular therapy. For this reason, although 
monitoring of cardiac functions is time-consuming and expensive, 
it is highly recommended before, during, and after chemotherapy 
to detect subclinical cardiac damage (  Figure 2  ,   Table 2  ). Accurate 
cardiovascular monitoring at regular intervals during chemo-
therapy is particularly important with prolonged adjuvant therapy. 
It would help to develop a series of diagnostic tools  —  instrumental, 
serological, or molecular  —  for early detection of cardiotoxicity and 
initiation of appropriate therapy to restore cardiac function and 
hemodynamics. It would also help to develop accurate guidelines 
for diagnosis and therapies to control cardiotoxic side effects, such 
as     -blockers and angiotensin-converting enzyme inhibitors (  5  ).                 
  One key and simple approach to monitor the effects of chemo-
therapy is arterial pressure measurement to identify hypertension. 
Hypertension is frequently seen in patients who are treated with 
several antiangiogenic agents (such as bevacizumab, sorafenib, and 
sunitinib) and can be severe (  74  ). Hypertension in the cancer 
patient under therapy needs to be promptly and adequately treated 
(  5  ,  54  ). 
  The most frequently used and effective approach to monitor 
cardiac function and its impairment by chemotherapy is evaluation 
of LVEF, which is commonly measured by echocardiography, a 
noninvasive technique. LVEF is one of the most important predic-
tors of prognosis; patients with substantially reduced ejection 
fractions typically have poorer prognosis. There is no clear inter-
national opinion on the frequency and method of LVEF assess-
ment. Both echocardiography and Multiple Gated Acquisition 
scanning can be used to assess LVEF and both techniques have 
advantages and disadvantages to be evaluated (  11  ). However, echo-
cardiographic LVEF assessment and angiography with radionu-
clides have shown low diagnostic sensitivity and low predictive 
power in detecting subclinical myocardial injury. The presence of 
HF heralds a much more serious prognosis than a change in 
LVEF, and HF can occur independently of a ﬁ  nding of a normal 
LVEF (  54  ). Other techniques, such as endomyocardial biopsy, 
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procedures. Thus, the quest for noninvasive and cost-effective 
diagnostic tools for the early identiﬁ  cation of patients who are 
susceptible to developing drug-induced cardiotoxicity needs to be 
increasingly pursued (  75  ). 
  The use of other indicators such as lipid proﬁ  le and serum 
markers for monitoring cardiotoxicity is being investigated. 
Biomarkers may provide important information regarding the 
pathogenesis of HF or the identiﬁ  cation of subjects at risk or may 
be useful in risk stratiﬁ  cation, in the diagnosis of HF, or in moni-
toring therapy (  76  ). Serum markers that detect damage of the 
myoﬁ  brils and of the cardiomyocytes, such as the different iso-
forms of troponin, are useful in detecting the acute cardiotoxicity 
that is mediated by therapeutic agents that induce cell death (  70  ). 
However, these markers do not appear to be valuable for detecting 
cardiotoxicity induced by nonclassical therapeutic agents or for 
detecting cardiotoxicity at early stages (  8  ). Cardiac natriuretic 
peptides, which are released during hemodynamic stress when the 
ventricles are dilated, hypertrophic, or subjected to increased wall 
tension, have been used as biomarkers, but deﬁ  nitive evidence is 
still lacking with regard to a diagnostic or prognostic role in pre-
dicting chemotherapy-induced cardiomyopathy (  71  ). It is clear 
that the diagnostic and prognostic value of other biomarkers used 
to monitor cardiovascular damage, such as myeloperoxidase (  72  ), 
should also be validated for clinical use in cardio-oncology. 
Genomics, proteomics, and/or recently identiﬁ  ed  oligoclonal 
B-cell repertoires (  77  ) may provide us with genomic proﬁ  les and 
serological biomarkers for assessment of cardiotoxicity in the fore-
seeable future.   
    From Risk Identification to Monitoring and Rescue by the 
Cardio-Oncologist 
  As stated throughout this review, cardiologists and oncologists 
must work together to improve disease prognosis and patient 
overall survival. To date, no guidelines have been developed spe-
cifically for the definition, detection, or therapy of cardiotoxicity 
from antineoplastic therapy, so it is imperative that these guide-
lines be defined. Meanwhile, cancer patients with cardiovascular 
diseases should be treated based on the guidelines published by the 
American College of Cardiology and American Heart Association 
(    www  .  acc  .  org  /  qualityandscience  /  clinical  /  statements  .  htm    ). We 
propose a possible flowchart of an integrated approach (  Figure 2  , 
  Table 2  ). Prevention of cardiotoxicity begins before the initiation 
of cancer therapy, with the oncologist and the cardiologist working 
as a team, the former performing a complete history and objective 
evaluation of the patient regarding cancer therapy or prevention 
and the latter evaluating cardiovascular parameters and function. 
Blood hematochemical parameters will be measured together with 
blood pressure, electrocardiogram      , dynamic electrocardiogram, 
Eco-Doppler to assess volume and thickness of heart chambers, 
LVEF, ST       interval evaluation, assessment of rhythm disturbances, 
and presence of valvular dysfunction. Patients with LVEF less 
than 50%, HF, severe or instable angina, aortic-coronary bypass, 
previous stroke or transient ischemic attacks, thromboembolic 
events, hypertension poorly responding to treatment, or severe 
arrhythmias should receive particular attention during the course 
of anticancer therapy because their risk of developing adverse 
events due to cardiotoxicity is elevated (  Figure 2  ,   Table 2  ). This 
assessment of the cardiovascular profile by the cardiologist should 
then be taken into consideration by the oncologist in deciding the 
therapeutic approach, in terms of drug selection and schedule, for 
each individual patient. 
  The dose of the anticancer drug administered during each ses-
sion, cumulative dose, schedule of delivery, route of administra-
tion, combination of drugs given, and sequence of drug 
administration are important factors to be considered to avoid 
cardiotoxicity (  12  ). Drug formulation is also important. For 
  Table 2    .       Cardiovascular monitoring of cancer patients  *           
    Approach Before antineoplastic therapy    †    During antineoplastic therapy    ‡     and follow-up   
    Clinical assessment Familial and personal anamnesis; physical examination; 
  diagnosis; risk assessment (  5  ); (    www  .  acc  .  org  /
   qualityandscience  /  clinical  /  statements  .  htm  ) 
Physical examination; cancer therapy evaluation (ctep.info.nih.gov); 
  risk reassessment (  5  ); (    www  .  acc  .  org  /  qualityandscience  /
   clinical  /  statements  .  htm  )   
  Tests Blood pressure assessment; chest radiography; LVEF 
  evaluation by any of these means: ECG, dynamic ECG, 
  Eco-Doppler, MUGA scanning (  5  ,  11  )
Blood pressure assessment; chest radiography; LVEF follow-up 
  by any of these means: ECG, dynamic ECG, Eco-Doppler, 
  MUGA scanning (  5  ,  11  ) 
  Serum markers Troponin isoforms; B-type natriuretic peptide; 
 myeloperoxidase  (  5  ,  70    –    72  )
Troponin isoforms; B-type natriuretic peptide myeloperoxidase 
 (  5  ,  70    –    72  ) 
  Prevention-
Treatment
Lifestyle adjustments; cardioprotection; ACE inhibitors; 
  angiotensin II receptor blockers;     -blockers; prevention 
  of thromboembolism with aspirin or anticoagulants or 
  platelet antiaggregants (  5  ,  63  ); (    www  .  acc  .  org  /
   qualityandscience  /  clinical  /  statements  .  htm  ) 
ACE inhibitors; angiotensin II receptor blockers;     -blockers; 
  cardiologic therapeutic regimen titration; other appropriate 
  therapies (ie, anticoagulant therapies); change of 
  antineoplastic therapeutic regimen (drug, schedule, or 
 suspension)  (  5  ,  47  ); (    www  .  acc  .  org  /  qualityandscience  /  clinical  /
   statements  .  htm  )     
    *     ACE    =    angiotensin-converting enzyme; ECG    =    electrocardiogram; LVEF    =    left ventricular ejection fraction; MUGA    =    multiple gated acquisition.   
      †       In our approach, we propose to perform a preliminary evaluation 10 days before beginning of the antineoplastic therapy. Different schedules can be followed 
(  3  ,  73  ).   
      ‡       In the proposed protocol, we suggest a cardiovascular evaluation at 2 and 4 weeks after the beginning of the antineoplastic therapy, followed by physical and 
instrumental evaluation every 6 weeks throughout the course of the treatment, different schedules can be followed (  3  ,  73  ). In our approach, physical and instru-
mental evaluation could be set after 3, 6, 12, 18, and 24 months after ending antineoplastic therapy. Schedule may change depending on the clinician’s judgment, 
different schedules can be followed (  3  ,  73  ).     jnci.oxfordjournals.org    JNCI | Review 21
   
    Figure 3    .       Examples of major mechanisms causing cardiotoxicity of anticancer treatments (  black text  ), clinically used therapeutic agents (  green text  ), 
and potential protective agents (  blue cursive text  ). ROS          =    reactive oxygen species; ACE    =    angiotensin-converting enzyme, NSAIDs    =    nonsteroidal 
anti-inﬂ  ammatory drugs.         
example, paclitaxel is formulated in a Cremophor EL vehicle to 
enhance the drug solubility, and it has been suggested that the 
vehicle and not the cytotoxic drug itself is responsible for cardiac 
rhythm disturbances, possibly via histamine release causing con-
duction disturbances and arrhythmias, as shown in animal models, 
or alternatively by affecting subcellular organelles and inducing 
cardiac muscle damage (  31  ). However, cardiac rhythm distur-
bances are not reported with use of other drugs containing 
Cremophor EL, such as cyclosporine (  31  ). Changes of drug 
administration and dosage have been also suggested to prevent 
cardiotoxicity. One approach for trastuzumab therapy is to sched-
ule short-course treatment concurrently with nonanthracycline-
based chemotherapy followed by anthracyclines in a block-sequential 
design (  78  ). Others use nonanthracycline-based regimens or 
targeted anthracyclines [reviewed in (  11  )]. 
  Because cardiovascular function changes in response to stress 
and other external inﬂ  uences on the individual patient, we feel that 
a cardiovascular follow-up of the treated patients should be peri-
odically scheduled; for example, 2 weeks after the beginning of the 
cancer therapy, followed by another after 4 weeks, then regular 
examinations every 6 weeks for the duration of therapy, and later 
during follow-up. The follow-up ideally would include a complete 
reevaluation of the cardiovascular parameters as in the baseline 
exam and a reassessment of the anticancer regimen by the 
oncologist. 
  If a cardiovascular event occurs during therapy, drug with-
drawal, with or without additional therapy directed at the HF, such 
as angiotensin-converting enzyme inhibitors and/or angiotensin II 
receptor antagonists and/or     -blockers, should be considered. 
This type of approach has been found effective in treating drug-
induced cardiotoxicity in most patients undergoing therapy with 
anthracyclines, but not those in therapy with targeted agents 
(  5  ,  79  ,  80  ). There are reports that antihypertensive, antiarrhythmic, 
and cardioprotective drugs defend against drug-induced cardiotox-
icity with a dual mechanism, protecting cardiovascular function 
while inhibiting tumor angiogenesis (  81    –    87  ). Careful clinical ap-
proaches will allow for eventual adjustment of the follow-up 
approach, in particular with regard to baseline patient risk and the 
speciﬁ  c therapeutic agent(s) and schedule used. 
  Long-term surveillance in cancer survivors is also indicated. 
The survivors of childhood cancer are more likely than survivors 
of adult cancer to experience cardiac damage and to require man-
agement (  88  ). Moreover, a Swedish retrospective study on long-
term risk of cardiovascular disease in Hodgkin lymphoma survivors 
(  54  ) showed that Hodgkin lymphoma survivors had an increased 
risk for being admitted to the hospital for cardiovascular diseases 
occurring after more than 20 years since their diagnosis with lym-
phoma, as compared with the general Swedish population. 
  It is clear that the oncology community needs to work toward 
developing guidelines for early assessment of cardiac risk as well as 
identiﬁ   cation and treatment of cardiotoxicity in the oncologic 
patient. Clinical studies are needed to deﬁ  ne these approaches and 
their application.   
    Future Perspectives: Chemoprevention of Cardiotoxicity 
Induced by Cancer Treatments 
  Moving toward a protective chemoprevention approach, several 
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without losing antitumor activity, and possibly even to enhance 
antitumor activity (  Figure 3  ). Most of these approaches are still 
experimental; however, some could easily be considered for clin-
ical trials. Dexrazoxane, a cyclic derivative of EDTA that chelates 
iron and thereby prevents the generation of cardiotoxic reactive 
oxygen species, is a drug used to protect the myocardium from 
anthracycline-induced cardiotoxicity (  89  ). At high concentra-
tions, dexrazoxane also inhibits topoisomerase II, which may also 
be involved in its cardioprotective activities (  89  ). Data from nine 
clinical studies that had enrolled a total of 1403 patients who 
received anthracycline-based therapy for advanced breast cancer 
showed an overall benefit from dexrazoxane in protecting cancer 
patients from anthracycline-induced HF (  90  ). However, this 
drug may increase the risk of adverse effects, such as a slightly 
higher incidence of myelosuppression, infection, and fever. 
An early dropout rate was also higher in patients who received 
dexrazoxane (  91  ).         
  Preexisting medical conditions and therapies modify the risk of 
cardiotoxicity in cancer patients. Lipid-lowering agents have been 
indicated as protective agents against anthracycline-mediated car-
diotoxicity (  92  ), and, in particular, statins seem to have a chemo-
preventive and direct antitumor effect (  93  ,  94  ). Whether statins 
may have protective or harmful effects on cancer risk is still a 
matter of debate, but the most recent reviews of the literature 
suggest that these drugs do not have short-term negative conse-
quences on cancer risk (  95  ); moreover, they can have an anti-
thrombotic effect (  96  ) that could lower the risk of thrombosis 
induced by anticancer treatment. 
  Antioxidants such as the glutathione precursor and analogue 
  N  -acetyl-  l  -cysteine (NAC) can be given to patients at relatively 
high levels and have an excellent toxicity proﬁ  le. NAC showed 
protective (  97  ) and synergistic antitumor and antimetastatic 
(  98  ,  99  ) effects in murine models, but it had no effect in reversing 
long-standing doxorubicin-induced cardiomyopathy in a trial 
that evaluated 19 sarcoma patients (  100  ). Numerous antioxidants 
and free radical scavengers found in dietary components such as 
polyphenols and ﬂ  avonoids, vitamins, micronutrients, enzymes, 
and hormones, such as selenium, zinc, coenzyme Q10, and 
melatonin, also show promise. Several plant derivatives, such 
as extracts from Gingko biloba (  101  ) and grape seed (  102  ) as 
well as polyphenols that were previously investigated for their 
antiangiogenic, anti-inﬂ   ammatory, and anticancer activities 
(Epigallocatechin-3-gallate from green tea, resveratrol from red 
wine, and curcumin from curry) (  103    –    108  ), have been found to 
have cardioprotective activity in experimental studies. Preclinical 
and clinical studies suggested that the anthracycline-induced car-
diotoxicity could be prevented by administering coenzyme Q10 
(  109  ).   l  -Carnitine, a quaternary ammonium compound synthe-
sized from methionine and lysine that is required for oxidative 
metabolism in mitochondria, has been proposed as a supplement 
to reduce the cardiotoxicity of epirubicin (  110  ). However, in spite 
of theoretical expectations and encouraging results obtained in 
experimental models, all randomized controlled trials in which 
potential cardioprotective agents (coenzyme Q10,   l  -carnitine, 
carvedilol, NAC, and combinations of vitamins E and C with 
NAC) (  90  ) were tested in cancer patients receiving anthracyclines 
had methodological limitations. Furthermore, the limited data 
from clinical trials on the use of vitamin E did not lead to ﬁ  rm 
conclusions (  90  ). 
  Because damage to the endothelium appears to be the under-
lying mechanism for the cardiotoxicity of a variety of chemothera-
peutic drugs, agents that prevent endothelial cell apoptosis should 
provide protective effects. Investigation of some antiangiogenic 
compounds, in particular those that target the nuclear factor     B 
pathway, have       also been found to render endothelial cells more 
resistant to apoptosis induced by external stimuli. These include 
NAC (  111  ,  112  ) and deguelin (  113  ). However, xanthohumol (  114  ) 
and triterpenoids (  115  ) did not perturb endothelial cell viability in 
vitro. The concept is that these agents force the endothelial cell 
into a quiescent state that leads to increased resistance to apoptosis 
(  116    –    118  ). 
  Because the pathogenesis of both cardiovascular disease and 
cancer is frequently linked to inﬂ  ammation, it follows that preven-
tion of inﬂ  ammation should protect from both diseases. NSAIDs 
such as aspirin are known to provide cardioprotective beneﬁ  t par-
ticularly in men; aspirin use has also been found to reduce risk for 
colorectal cancer (  119  ), breast cancer (  120  ,  121  ), and other cancers 
(  122  ). Development of cardioprotection during and after cancer 
therapy is another area that needs to be focused on to translate 
laboratory discoveries into clinical trials and to develop consensus 
protocols.     
    Conclusions 
  Cardiotoxicity is becoming one of the most important complica-
tions of cancer chemotherapy and, sometimes, of cancer chemo-
prevention. Identification of those patients at higher risk will be 
one key strategy to reduce the morbidity and mortality from car-
diotoxicity. However, current screening methods are cumbersome 
and lack sufficient predictive power. Thus, the discovery of new 
biomarkers to identify patients at a high risk for the development 
of these complications is a high priority. Guidelines for cancer 
treatment that take cardiologic conditions into account are cur-
rently lacking and need to be developed. Furthermore, because 
many major chemotherapeutic agents used in the treatment of 
cancer are associated with strong adverse effects on the cardiovas-
cular system, a key goal will be identification of new compounds 
such as antioxidants and endothelial- or cardiomyocyte-protective 
agents that can prevent cardiotoxicity. Last but not least, assess-
ment of cardiotoxicity should become part of phase I trials to 
develop agents with less risk. 
  It is important to consider that the approach of cardiologists to 
the deﬁ  nition of disease is quite different from that of the oncolo-
gists. Therefore, to perform interdisciplinary medicine, there is a 
risk that many concepts and observations may well be “lost in 
translation” (  123  ). We feel that there is a need to train a generation 
of “cardio-oncologist” or “onco-cardiologist” investigators and 
clinicians to overcome these communication gaps. Finally, we need 
to take into consideration risk  –  beneﬁ  t (or in this case, risk  –  risk) 
proﬁ  les. It is clear that for cancers with very poor prognosis, even 
with very aggressive therapy, cardiovascular risks fall to a lower 
priority. In cancers with high probability of long-term survival, 
such as breast and prostate cancers, it is very important to consider 
cardiovascular risks. For the vast majority of cancers that lie jnci.oxfordjournals.org    JNCI | Review 23
in-between, cardio-oncology needs to be brought increasingly into 
practice.   
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